Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Limited

http://www.lupin.com

Latest From Lupin Limited

After Ups and Downs, Industry Attempts To Normalize In Q3

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

Coronavirus COVID-19 Generic Drugs

Lupin Gives Direction On Pegfilgrastim And Ranibizumab

Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.

Biosimilars Generic Drugs

BI India’s First Woman MD May Have To Hit The Ground Running

The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.

India Commercial

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

India Intellectual Property
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
    • Drug Delivery
      • Controlled Release
      • Pulmonary
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Temmler Pharma GmbH & Co.
    • YL Biologics (YLB)
    • ZAO Biocom
    • Kyowa Pharmaceutical Industry Co., Ltd.
    • Symbiomix Therapeutics, LLC.
UsernamePublicRestriction

Register